Transcatheter Mitral Valve Implantation — Is This the Next Big Thing?

A first-in-human trial report

The search for a nonsurgical alternative to treat severe mitral regurgitation (MR), particularly for patients with surgical contraindications, has been energized by the successes of transcatheter aortic valve replacement (TAVR) and MitraClip transcatheter repair of MR. Investigators now report the first results with a novel transcatheter mitral valve implantation (TMVI) system (Tiara). The device is a nitinol, self-expanding, trileaflet, bovine pericardial prosthesis that is inserted transapically with a 32-French delivery device and anchors to the trigones, leaflets, and posterior annulus. Two of the authors report financial ties to the device manufacturer.

Both patients treated in this report had severe secondary MR, severe left ventricula…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)